Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways.

Kreth S, Ledderose C, Luchting B, Weis F, Thiel M.

Shock. 2010 Jul;34(1):10-6. doi: 10.1097/SHK.0b013e3181cdc3e2.

PMID:
19997047
2.
3.
4.

LPS-stimulated PMN activation and proinflammatory mediator synthesis is downregulated by phosphodiesterase inhibition: role of pentoxifylline.

Coimbra R, Loomis W, Melbostad H, Tobar M, Porcides RD, Hoyt DB.

J Trauma. 2004 Dec;57(6):1157-63.

PMID:
15625444
5.
6.

Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities.

Lin Y, Goebels J, Rutgeerts O, Kasran A, Van Gool S, Ceuppens J, Schönharting M, Waer M.

Transplantation. 1997 Jun 27;63(12):1813-8.

PMID:
9210510
7.

Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells.

Schandené L, Vandenbussche P, Crusiaux A, Alègre ML, Abramowicz D, Dupont E, Content J, Goldman M.

Immunology. 1992 May;76(1):30-4.

8.

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.

Weber F, Polak T, Günther A, Kubuschok B, Janovskaja J, Bitsch A, Poser S, Rieckmann P.

Ann Neurol. 1998 Jul;44(1):27-34.

PMID:
9667590
9.

Mediator-dependent effects of pentoxifylline on endothelium for transmigration of neutrophils.

Schratzberger P, Dunzendorfer S, Reinisch N, Buratti T, Kähler CM, Tilg H, Herold M, Wiedermann CJ.

Immunopharmacology. 1999 Jan;41(1):65-75.

PMID:
9950270
10.

Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A.

Funk JO, Ernst M, Schönharting MM, Zabel P.

Int J Immunopharmacol. 1995 Dec;17(12):1007-16.

PMID:
8964650
11.

Immune response modulation by pentoxifylline in vitro.

Tilg H, Eibl B, Pichl M, Gächter A, Herold M, Brankova J, Huber C, Niederwieser D.

Transplantation. 1993 Jul;56(1):196-201.

PMID:
8333042
12.
13.

The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.

Liang L, Beshay E, Prud'homme GJ.

Diabetes. 1998 Apr;47(4):570-5.

PMID:
9568689
14.

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.

Rieckmann P, Weber F, Günther A, Martin S, Bitsch A, Broocks A, Kitze B, Weber T, Börner T, Poser S.

J Neuroimmunol. 1996 Feb;64(2):193-200.

PMID:
8632062
15.
16.

The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells.

Bshesh K, Zhao B, Spight D, Biaggioni I, Feokistov I, Denenberg A, Wong HR, Shanley TP.

J Leukoc Biol. 2002 Nov;72(5):1027-36.

PMID:
12429726
17.

Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide.

Fortin A, Harbour D, Fernandes M, Borgeat P, Bourgoin S.

J Leukoc Biol. 2006 Mar;79(3):574-85. Epub 2005 Dec 30.

PMID:
16387843
18.
19.

Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules.

Noel C, Copin MC, Hazzan M, Labalette M, Susen S, Lelievre G, Dessaint JP.

Transplantation. 2000 Mar 27;69(6):1102-7.

PMID:
10762214
20.

In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.

Hecht M, Müller M, Lohmann-Matthes ML, Emmendörffer A.

J Leukoc Biol. 1995 Feb;57(2):242-9.

PMID:
7852838

Supplemental Content

Support Center